Colchicine Toxicity in End-Stage Renal Disease Patients: A Case-Control Study

Basit Öğe Kaydı
dc.contributor.authorSolak, Yalcin
dc.contributor.authorAtalay, Huseyin
dc.contributor.authorBiyik, Zeynep
dc.contributor.authorAlibasic, Hayrudin
dc.contributor.authorGaipov, Abduzhappar
dc.contributor.authorGuney, Figen
dc.contributor.authorKucuk, Adem
dc.date.accessioned2024-02-23T14:21:16Z
dc.date.available2024-02-23T14:21:16Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractColchicine has been used in a number of disorders. Because colchicine is partially excreted from the kidney, there is a need for dose reduction in case of renal functional impairment. There are no data with regards to safe dosing schedule of colchicine in hemodialysis patients. We aimed to evaluate adverse effects of colchicine use in a hemodialysis cohort. We screened hemodialysis patients who were using colchicine for any reason. All patients were interviewed regarding possible toxicities of colchicine use and were examined with a special focus on neuromuscular system. Creatine kinase and myoglobin were used to detect any subclinical muscle injury or rhabdomyolysis, respectively. Twenty-two maintenance hemodialysis patients who were on colchicine for more than 6 months and 20 control hemodialysis patients not using colchicine were included in the study. Four of 22 patients were using 0.5 mg/day, 4 patients were using 1.5 mg/day, and 14 patients were using 1 mg/day colchicine. Mean duration for colchicine use was 8.9 +/- 8.2 years. There was no difference between the groups in terms of myoneuropathic signs and symptoms and blood counts except for white blood cell count, which was significantly higher in patients on colchicine. Serum creatine kinase (56.3 +/- 39.5 and 52.1 +/- 36.1 for colchicine and control groups, respectively, P = 0.72) and myoglobin (191.4 +/- 108.8 and 214.6+/-83.5 for colchicine and control groups, respectively, P = 0.44) levels were not different between the groups. We conclude that in a small number of haemodialysis patients who were apparently tolerating colchicine, detailed assessment revealed no evidence of sublinical toxicity when compared with controls.en_US
dc.description.sponsorshipERA-EDTA fellowship programen_US
dc.description.sponsorshipThe author A. G. received grant support from the ERA-EDTA fellowship program. No sources of funding were used to conduct this study or prepare this article.en_US
dc.identifier.doi10.1097/MJT.0b013e31825a364a
dc.identifier.endpageE195en_US
dc.identifier.issn1075-2765
dc.identifier.issn1536-3686
dc.identifier.issue6en_US
dc.identifier.pmid22874645en_US
dc.identifier.scopus2-s2.0-84914157803en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE189en_US
dc.identifier.urihttps://doi.org/10.1097/MJT.0b013e31825a364a
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13521
dc.identifier.volume21en_US
dc.identifier.wosWOS:000345012600003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAmerican Journal Of Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColchicineen_US
dc.subjectAdverse Effecten_US
dc.subjectToxicityen_US
dc.subjectHemodialysisen_US
dc.titleColchicine Toxicity in End-Stage Renal Disease Patients: A Case-Control Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu